Plus Therapeutics WKN: A2PPX6 ISIN: US72941H4002 Forum: Aktien Thema: Hauptdiskussion

Jo aber mit anderen Runs ;)

Es können noch ganz andere kurse kommen↗️

Wo wollen die denn hin 😂

Oh yes👌

Schönes Volumen

Nice..

Morgen 🤗

Moin 🙋‍♀️

✌️

👍

Klingt gut👍

The oral presentation, titled Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases Phase 1/2a Dose Escalation Trial [LOCL-04], demonstrated that the 186RNL dose administered through an intraventricular catheter at 6.6 mCi in 5.0 mL achieved absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid space, which was well tolerated with no treatment-related adverse events of greater than grade 1. Furthermore, all three patients in the cohort were observed to have prompt and complete 186RNL distribution throughout the cerebrospinal fluid (CSF) subarachnoid space that was durable past one week and very well tolerated. Importantly, all patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 65% to 92% which was also durable. “While we can draw only limited conclusions from the first patient cohort, these findings suggest that the application of locally delivered and highly targeted 186RNL for the treatment of LM has the potential to be an effective and safe treatment for patients,” stated Norman LaFrance, M.D., Chief Medical Officer and SVP at Plus Therapeutics. “Leptomeningeal metastases are a devastating complication of cancer that often force patients to choose between toxic therapies or a limited life expectancy that builds on top of the already complex burden of their underlying cancer. However, our approach to deliver 186RNL is precisely targeted to the CNS and minimizes radiation exposure to other parts of the body and importantly has the potential to extend patient survival,” said Andrew J. Brenner, M.D., Ph.D., Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-LM clinical trial. “We look forward to continuing the clinical evaluation with additional dose escalations to further assess 186RNL’s versatility and on behalf of patients in need.”

Ist aber schon ins rollen gekommen.ist mir zu heiß😅

Bei meinen Broker reichen mir die Anfangsbuchstaben….. A2JCM4

Gibt einige schöne kandidaten wo extrem wenig aktien im umlauf sind und nur auf aufmerksamkeit warten🤣

Wkn ?